Huizenga Theodore Alan 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Jan 2, 2024
Insider Transaction Report
Form 4
Huizenga Theodore Alan
SVP, Chief Accounting Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-01-02−3,000→ 0 totalExercise: $21.00Exp: 2024-01-29→ Common Stock (3,000 underlying) - Exercise/Conversion
Common Stock
2024-01-02$21.00/sh+3,000$63,000→ 27,892 total - Award
Common Stock
2023-12-20+1,000→ 24,614 total
Footnotes (4)
- [F1]Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
- [F2]Includes 278 shares acquired under the Company's Amended and Restated 2014 Employee Stock Purchase Plan on October 31, 2023.
- [F3]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F4]1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter.